Table 2 Summary of all crystal structures of MLKL pseudokinase domain to date
From: Phosphorylation-dependent pseudokinase domain dimerization drives full-length MLKL oligomerization
PDB | Species | Variant | Ligand | Residue range | Space groupa | Conformation | Reference | ||
---|---|---|---|---|---|---|---|---|---|
Salt bridge (VAIK-αC) | R-spine | DFG | |||||||
4MWI | Human | – | – | 190–471 | C 2 2 21 | Yes | Yes | In | |
8SLZ | Human | pT357/pTS358 | – | 190–471 | C 2 2 21 | Yes | Yes | In | This study |
4M67 | Human | – | – | 179–471 | C 2 2 21 | Yes | Yes | In | |
6LK6 | Human | T357A/S358A | – | 179–471 | C 2 2 21 | Yes | Yes | In | |
6LK5 | Human | T357E/S358D | – | 179–471 | C 2 2 21 | Yes | Yes | In | |
6BWK | Human | T357E/S358E | – | 190–471 | C 2 2 21 | Yes | Yes | In | |
5KO1 | Human | – | Compound 4 (Type I inhibitor) | 191–471 | C 2 2 21 | Yes | Yes | In | |
5KNJ | Human | – | Compound 1 (Type II inhibitor) | 191–471 | P 21 21 21 | Yes | No | Out | |
6O5Z | Human | – | Compound 2 (Type II inhibitor) | 190–471 | P 21 | Yes | No | Out | |
7JW7 | Human | – | Mb27 (protein) | 190–471 | P 31 2 1 | Yes | Yes | In | |
7JXU | Human | – | Mb32 (protein) | 190–471 | P 43 | No | No | In | |
7MON | Human | – | RIPK3 (protein) | 190–471 | P 21 21 21 | No | No | In | |
4BTF | Mouse | – | – | 1–464 | P 21 21 21 | No | No | In | |
4M69 | Mouse | – | RIPK3 (protein) | 182–464 | C 2 2 21 | No | No | Out | |
4M68 | Mouse | – | – | 182–464 | P 21 | No | No | In | |
6VC0 | Horse | – | – | 188–475 | C 2 | Yes | Yes | In | |
6VBZ | Rat | – | – | 179–464 | P 61 2 2 | Yes | Yes | In |